IP Library Granted Patent US 9,233,170
Granted Patent B2
US 9,233,170 · App. 14/158,179 · Granted Jan 12, 2016

Interfering RNA delivery system and uses thereof

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,233,170
App. No.
14/158,179
Granted
Jan 12, 2016
Kind
B2
Abstract

The invention provides a delivery system comprising a cell penetrating peptide, a polyarginine peptide, and an interfering RNA molecule. The system can be used for delivering interfering RNA molecules into a cell in vivo or in vitro. Therapeutic uses for the delivery system are also provided.

Claims (14)

1. An interfering RNA delivery system comprising an interfering RNA molecule linked to a cell penetrating peptide (CPP)-Arg peptide wherein the CPP-Arg peptide comprises the sequence as set forth in SEQ ID NO: 3.

2. The delivery system of claim 1 , wherein the CPP-Arg peptide further comprises an HA2 peptide.

3. The delivery system of claim 1 , wherein the interfering RNA molecule is linked to the CPP-Arg peptide via a covalent bond.

4. The delivery system of claim 1 , wherein the interfering RNA molecule is a siRNA, miRNA, or shRNA.

5. A pharmaceutical composition comprising the delivery system of claim 1 and a pharmaceutically acceptable carrier.

6. A method of treating an ocular disorder in a patient, comprising administering to the patient the interfering RNA delivery system of claim 1 , wherein the interfering RNA molecule can attenuate expression of a gene associated with the ocular disorder.

7. A method of delivering an interfering RNA molecule into a cell, comprising:

(a) attaching an interfering RNA molecule to a CPP-Arg peptide wherein the CPP-Arg peptide comprises the sequence as set forth in SEQ ID NO: 3, thereby forming an interfering RNA delivery system; and

(b) administering the interfering RNA delivery system to the cell under conditions suitable for the system to enter the cell.

8. The method of claim 7 , wherein release of the system from the endosome inside the cell is enhanced in the presence of an HA2 peptide.

9. The method of claim 8 , wherein the HA2 peptide is introduced into the cell by administration of a CPP-HA2 peptide.

10. The method of claim 7 , wherein the CPP-Arg peptide further comprises the HA2 peptide.

11. The method of claim 7 , wherein the interfering RNA molecule is linked to the CPP-Arg peptide via a covalent bond.

12. The method of claim 7 , wherein the interfering RNA molecule is a siRNA, miRNA, or shRNA.

Assignments (4)
CHANGE OF NAME Recorded Aug 12, 2024
From: ARROWHEAD RESEARCH CORPORATION
To: ARROWHEAD PHARMACEUTICALS, INC.
Reel/Frame 068552/0799 →
SECURITY INTEREST Recorded Aug 7, 2024
From: ARROWHEAD PHARMACEUTICALS, INC.
To: SIXTH STREETLENDING PARTNERS, AS THE ADMINISTRATIVE AGENT
Reel/Frame 068510/0363 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 13, 2015
From: ALCON RESEARCH, LTD.
To: ARROWHEAD RESEARCH CORPORATION
Reel/Frame 035653/0635 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 17, 2014
From: CHATTERTON, JON E.
To: ALCON RESEARCH, LTD
Reel/Frame 031996/0645 →